Cellebrite DI Ltd. (NASDAQ:CLBT) Given Average Recommendation of “Buy” by Brokerages

Shares of Cellebrite DI Ltd. (NASDAQ:CLBTGet Free Report) have received an average rating of “Buy” from the eight research firms that are currently covering the firm, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $20.57.

Several research analysts have recently issued reports on CLBT shares. Needham & Company LLC upped their price objective on Cellebrite DI from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. upped their price objective on Cellebrite DI from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Monday. Craig Hallum increased their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, TD Cowen increased their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Monday, September 23rd.

Read Our Latest Report on Cellebrite DI

Cellebrite DI Price Performance

Cellebrite DI stock opened at $20.23 on Friday. The business has a 50 day moving average of $19.02 and a 200-day moving average of $15.95. Cellebrite DI has a 1 year low of $7.91 and a 1 year high of $21.72. The company has a market capitalization of $4.17 billion, a P/E ratio of -13.05, a P/E/G ratio of 2.71 and a beta of 1.51.

Cellebrite DI (NASDAQ:CLBTGet Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.05. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The company had revenue of $106.90 million during the quarter, compared to the consensus estimate of $102.06 million. During the same quarter in the prior year, the firm posted $0.09 earnings per share. The firm’s revenue was up 27.0% compared to the same quarter last year. Equities analysts anticipate that Cellebrite DI will post 0.32 EPS for the current year.

Institutional Trading of Cellebrite DI

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLBT. Quarry LP bought a new position in shares of Cellebrite DI during the 3rd quarter worth approximately $27,000. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Cellebrite DI by 59.6% during the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock worth $33,000 after buying an additional 1,017 shares in the last quarter. Advisors Asset Management Inc. boosted its holdings in shares of Cellebrite DI by 130.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock worth $52,000 after buying an additional 1,742 shares in the last quarter. Pathway Financial Advisers LLC boosted its holdings in shares of Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock worth $74,000 after buying an additional 4,118 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado bought a new position in shares of Cellebrite DI during the 2nd quarter worth approximately $71,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Company Profile

(Get Free Report

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Read More

Analyst Recommendations for Cellebrite DI (NASDAQ:CLBT)

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.